Antimicrobial stewardship programs in seven Latin American countries: facing the challenges

Descripción del Articulo

Background: Studies have shown that more than 50% of the antibiotics used in hospitals are unnecessary or inappropriate and, that antimicrobial resistance may cost up to 20 billion USD in excess medical costs each year. On the other hand, Antimicrobial Stewardship Programs (ASP) significantly reduce...

Descripción completa

Detalles Bibliográficos
Autores: Pallares, CJ, Porras, J, De-La-Cadena, E, Garcia-Betancur, JC, Restrepo-Arbelaez, N, Viveros, SMC, Cornistein, W, Castaneda-Mendez, P, Cuellar, L, Boldim-Ferreira, D, Chaverri-Murillo, J, Labarca, JA, Villegas, MV
Formato: artículo
Fecha de Publicación:2023
Institución:Instituto Nacional de Enfermedades Neoplásicas
Repositorio:INEN-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorio.inen.sld.pe:inen/189
Enlace del recurso:https://repositorio.inen.sld.pe/handle/inen/189
Nivel de acceso:acceso abierto
Materia:Antimicrobial resistance
Antimicrobial stewardship
Antimicrobial stewardship programs
Latin America
https://purl.org/pe-repo/ocde/ford#3.02.21
id INEN_ffdbbfdc3bf9bf56b0225db334007c8c
oai_identifier_str oai:repositorio.inen.sld.pe:inen/189
network_acronym_str INEN
network_name_str INEN-Institucional
repository_id_str .
spelling Pallares, CJPorras, JDe-La-Cadena, EGarcia-Betancur, JCRestrepo-Arbelaez, NViveros, SMCCornistein, WCastaneda-Mendez, PCuellar, LBoldim-Ferreira, DChaverri-Murillo, JLabarca, JAVillegas, MV2024-11-27T17:33:21Z2024-11-27T17:33:21Z2023Background: Studies have shown that more than 50% of the antibiotics used in hospitals are unnecessary or inappropriate and, that antimicrobial resistance may cost up to 20 billion USD in excess medical costs each year. On the other hand, Antimicrobial Stewardship Programs (ASP) significantly reduce inappropriate antimicrobial use, emergence of antimicrobial resistance, healthcare associated infections, and costs in hospital settings. Objective: To evaluate the development of ASP and antibiotic savings in 7 Latin American hospitals using standardized quantitative indicators in all the participating health care institutions. Methods: An interventional study was conducted, where pre- and post- evaluations were performed using a standardized score tool adapted from the Joint Commission International accreditation standards and, the Colombian Institute of Technical Standards and Certification. We evaluated ASP from 7 Latin American hospitals between 2019 and 2020. A pre-intervention evaluation was done in each hospital to quantify the degree of development of the ASP (ASP Development score). Based on these results, tailored on-site training was implemented in each hospital, followed by a post-intervention evaluation to quantify improvement of ASP-development indicators. In addition, monetary savings in antimicrobials derived from the ASP intervention were estimated. Results: In the pre-intervention evaluation, the average ASP development score for the 7 institutions was 65.8% (40-94.3%). The items with the lowest development score were those related to monitoring and communicating the ASP progress and success. For the post-intervention evaluation, 2 institutions couldn’t participate due to the pressure imposed by the COVID-19 pandemic. For the remaining 5/7 hospitals, the average ASP development score was 82.3% with an increase of 12.0% when compared to the pre-intervention measurement of the same institutions (average pre-intervention score 70.3% (48.2%-94.3%) The items with a significant increase were key performance indicators, AMS education and training of the prescribers. Three of the seven (3/7) hospitals reported antibiotic monetary savings associated to the ASP intervention. Conclusions: The use of the tool described shown to be useful to evaluate specific areas of ASP-development that were lacking and tailor interventions for the participating hospitals, consequently, it helped improve ASP-development in the institutions that underwent pre- intervention and post-intervention analysis. In addition, the strategies showed monetary savings on antimicrobial costs when measured. © 2023, The Author(s).application/pdf10.1186/s12879-023-08398-3https://repositorio.inen.sld.pe/handle/inen/189engBMC Infectious DiseasesUKBioMed Central Ltdinfo:eu-repo/semantics/openAccesshttps//creativecomons.org/licenses/by/4.0/Antimicrobial resistanceAntimicrobial stewardshipAntimicrobial stewardship programsLatin Americahttps://purl.org/pe-repo/ocde/ford#3.02.21Antimicrobial stewardship programs in seven Latin American countries: facing the challengesinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:INEN-Institucionalinstname:Instituto Nacional de Enfermedades Neoplásicasinstacron:INENPublicationinen/189oai:repositorio.inen.sld.pe:inen/1892024-11-27 17:33:21.219https//creativecomons.org/licenses/by/4.0/info:eu-repo/semantics/openAccesshttps://repositorio.inen.sld.peRepositorio INENrepositorioinendspace@gmail.com
dc.title.none.fl_str_mv Antimicrobial stewardship programs in seven Latin American countries: facing the challenges
title Antimicrobial stewardship programs in seven Latin American countries: facing the challenges
spellingShingle Antimicrobial stewardship programs in seven Latin American countries: facing the challenges
Pallares, CJ
Antimicrobial resistance
Antimicrobial stewardship
Antimicrobial stewardship programs
Latin America
https://purl.org/pe-repo/ocde/ford#3.02.21
title_short Antimicrobial stewardship programs in seven Latin American countries: facing the challenges
title_full Antimicrobial stewardship programs in seven Latin American countries: facing the challenges
title_fullStr Antimicrobial stewardship programs in seven Latin American countries: facing the challenges
title_full_unstemmed Antimicrobial stewardship programs in seven Latin American countries: facing the challenges
title_sort Antimicrobial stewardship programs in seven Latin American countries: facing the challenges
author Pallares, CJ
author_facet Pallares, CJ
Porras, J
De-La-Cadena, E
Garcia-Betancur, JC
Restrepo-Arbelaez, N
Viveros, SMC
Cornistein, W
Castaneda-Mendez, P
Cuellar, L
Boldim-Ferreira, D
Chaverri-Murillo, J
Labarca, JA
Villegas, MV
author_role author
author2 Porras, J
De-La-Cadena, E
Garcia-Betancur, JC
Restrepo-Arbelaez, N
Viveros, SMC
Cornistein, W
Castaneda-Mendez, P
Cuellar, L
Boldim-Ferreira, D
Chaverri-Murillo, J
Labarca, JA
Villegas, MV
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Pallares, CJ
Porras, J
De-La-Cadena, E
Garcia-Betancur, JC
Restrepo-Arbelaez, N
Viveros, SMC
Cornistein, W
Castaneda-Mendez, P
Cuellar, L
Boldim-Ferreira, D
Chaverri-Murillo, J
Labarca, JA
Villegas, MV
dc.subject.none.fl_str_mv Antimicrobial resistance
Antimicrobial stewardship
Antimicrobial stewardship programs
Latin America
topic Antimicrobial resistance
Antimicrobial stewardship
Antimicrobial stewardship programs
Latin America
https://purl.org/pe-repo/ocde/ford#3.02.21
dc.subject.ocde.none.fl_str_mv https://purl.org/pe-repo/ocde/ford#3.02.21
description Background: Studies have shown that more than 50% of the antibiotics used in hospitals are unnecessary or inappropriate and, that antimicrobial resistance may cost up to 20 billion USD in excess medical costs each year. On the other hand, Antimicrobial Stewardship Programs (ASP) significantly reduce inappropriate antimicrobial use, emergence of antimicrobial resistance, healthcare associated infections, and costs in hospital settings. Objective: To evaluate the development of ASP and antibiotic savings in 7 Latin American hospitals using standardized quantitative indicators in all the participating health care institutions. Methods: An interventional study was conducted, where pre- and post- evaluations were performed using a standardized score tool adapted from the Joint Commission International accreditation standards and, the Colombian Institute of Technical Standards and Certification. We evaluated ASP from 7 Latin American hospitals between 2019 and 2020. A pre-intervention evaluation was done in each hospital to quantify the degree of development of the ASP (ASP Development score). Based on these results, tailored on-site training was implemented in each hospital, followed by a post-intervention evaluation to quantify improvement of ASP-development indicators. In addition, monetary savings in antimicrobials derived from the ASP intervention were estimated. Results: In the pre-intervention evaluation, the average ASP development score for the 7 institutions was 65.8% (40-94.3%). The items with the lowest development score were those related to monitoring and communicating the ASP progress and success. For the post-intervention evaluation, 2 institutions couldn’t participate due to the pressure imposed by the COVID-19 pandemic. For the remaining 5/7 hospitals, the average ASP development score was 82.3% with an increase of 12.0% when compared to the pre-intervention measurement of the same institutions (average pre-intervention score 70.3% (48.2%-94.3%) The items with a significant increase were key performance indicators, AMS education and training of the prescribers. Three of the seven (3/7) hospitals reported antibiotic monetary savings associated to the ASP intervention. Conclusions: The use of the tool described shown to be useful to evaluate specific areas of ASP-development that were lacking and tailor interventions for the participating hospitals, consequently, it helped improve ASP-development in the institutions that underwent pre- intervention and post-intervention analysis. In addition, the strategies showed monetary savings on antimicrobial costs when measured. © 2023, The Author(s).
publishDate 2023
dc.date.accessioned.none.fl_str_mv 2024-11-27T17:33:21Z
dc.date.available.none.fl_str_mv 2024-11-27T17:33:21Z
dc.date.issued.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
dc.type.version.none.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.doi.none.fl_str_mv 10.1186/s12879-023-08398-3
dc.identifier.uri.none.fl_str_mv https://repositorio.inen.sld.pe/handle/inen/189
identifier_str_mv 10.1186/s12879-023-08398-3
url https://repositorio.inen.sld.pe/handle/inen/189
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.ispartof.none.fl_str_mv BioMed Central Ltd
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.none.fl_str_mv https//creativecomons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https//creativecomons.org/licenses/by/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BMC Infectious Diseases
dc.publisher.country.none.fl_str_mv UK
publisher.none.fl_str_mv BMC Infectious Diseases
dc.source.none.fl_str_mv reponame:INEN-Institucional
instname:Instituto Nacional de Enfermedades Neoplásicas
instacron:INEN
instname_str Instituto Nacional de Enfermedades Neoplásicas
instacron_str INEN
institution INEN
reponame_str INEN-Institucional
collection INEN-Institucional
repository.name.fl_str_mv Repositorio INEN
repository.mail.fl_str_mv repositorioinendspace@gmail.com
_version_ 1841803035964080128
score 12.873224
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).